Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | PRCP | P42785 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14841048 | 1.00 | CYP3A4 (0.54) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL10192323 | 0.99 | CYP3A4 (0.52) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL12186089 | 0.92 | CYP3A4 (0.52) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL14849126 | 0.91 | CYP3A4 (0.66) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL17527196 | 0.91 | CYP3A4 (0.52) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL18727266 | 0.90 | CYP3A4 (0.51) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL18727347 | 0.90 | CYP3A4 (0.51) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL19620024 | 0.90 | CYP3A4 (0.64) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL4976901 | 0.90 | CYP3A4 (0.67) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL19619878 | 0.90 | CYP3A4 (0.51) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779156-B2 | Analogues for the treatment or prevention of flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130090351-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2550267-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011119853-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090351-A1 | ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | BLVRB, RRP1B, C1QBP | CYP3A4 1508/4885CYP2C9 2576/4885NR1I2 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.